Clinical Trial Diversity and Inclusion Plan Designer for FDA Draft Guidance Compliance for Audit Readiness Internal Audit Week for Compliance Review Change Review Cycle for Portfolio Prioritization Scenario 1575
Designs a comprehensive Diversity and Inclusion Plan for a Phase III clinical trial aligned to FDA's 2022 Draft Guidance on Diversity Action Plans, specifying enrollment targets, site selection criteria, and retention strategies by demographic group.